Oric Pharmaceuticals, Inc. (ORIC) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Oric Pharmaceuticals reported revenue of $0. Net income was -$129.5M, or -$1.47 per diluted share. Operating activities generated -$111.0M of cash, leaving -$111.7M of free cash flow. At fiscal year end, Oric Pharmaceuticals held $408.9M in total assets against $24.5M in total liabilities, including $45.7M of cash and equivalents.
Open the full interactive Oric Pharmaceuticals financials → Quarterly statements, key ratios, valuation history and price charts.
Oric Pharmaceuticals Key Stats
| Share Price | $11.31 |
|---|---|
| Market Cap | $1.22B |
| 52-Week Range | $7.47 – $14.65 |
| Shares Outstanding | 108.0 million (basic, 2026 Q2) |
Oric Pharmaceuticals Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$74.2M | -$78.9M | -$91.8M | -$110.8M | -$142.9M | -$143.0M |
| Pre-Tax Income | -$73.7M | -$78.7M | -$89.1M | -$100.7M | -$127.8M | -$129.5M |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$73.7M | -$78.7M | -$89.1M | -$100.7M | -$127.8M | -$129.5M |
| Diluted EPS | -$3.36 | -$2.07 | -$2.25 | -$1.96 | -$1.83 | -$1.47 |
Oric Pharmaceuticals Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$32.6M | -$30.5M | -$35.8M | -$41.5M |
| Diluted EPS | -$0.33 | -$0.35 | -$0.34 | -$0.38 |
Oric Pharmaceuticals Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $78.4M | $226.0M | $66.8M | $23.4M | $59.4M | $45.7M |
| Current Assets | $296.7M | $240.5M | $210.5M | $212.6M | $262.2M | $288.5M |
| Total Assets | $299.0M | $298.6M | $247.2M | $252.0M | $274.1M | $408.9M |
| Current Liabilities | $9.0M | $15.2M | $15.4M | $20.5M | $24.8M | $20.4M |
| Total Long-Term Debt | — | $10.5M | — | — | — | — |
| Total Liabilities | $9.2M | $25.7M | $24.8M | $27.9M | $31.0M | $24.5M |
| Shareholders' Equity | $289.8M | $273.0M | $222.4M | $224.1M | $243.1M | $384.4M |
Oric Pharmaceuticals Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$45.3M | -$59.5M | -$75.1M | -$85.7M | -$112.7M | -$111.0M |
| Cash From Investing | -$216.0M | $158.4M | -$109.2M | -$43.4M | $22.1M | -$148.0M |
| Cash From Financing | $250.5M | $49.1M | $25.2M | $85.7M | $126.5M | $245.3M |
| Free Cash Flow | -$45.9M | -$60.5M | -$77.2M | -$86.5M | -$113.8M | -$111.7M |
Figures from Oric Pharmaceuticals' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Oric Pharmaceuticals financials page for every line item.
Oric Pharmaceuticals Company Profile
| Ticker | ORIC |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | South San Francisco, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer |
| SEC CIK | 0001796280 |
Frequently Asked Questions
What was Oric Pharmaceuticals' revenue in fiscal 2025?
Oric Pharmaceuticals (ORIC) reported revenue of $0 for fiscal 2025.
What is Oric Pharmaceuticals' annual revenue history?
Oric Pharmaceuticals' annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Oric Pharmaceuticals' net income in fiscal 2025?
Oric Pharmaceuticals reported net income of -$129.5M for fiscal 2025.
What was Oric Pharmaceuticals' earnings per share (EPS) in fiscal 2025?
Oric Pharmaceuticals' diluted EPS was -$1.47 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Oric Pharmaceuticals generate in fiscal 2025?
Oric Pharmaceuticals generated -$111.7M of free cash flow in fiscal 2025.
What was Oric Pharmaceuticals' revenue last quarter?
In its most recent reported quarter (2026 Q2), Oric Pharmaceuticals reported revenue of $0.
How many shares of Oric Pharmaceuticals are outstanding?
Oric Pharmaceuticals reported a weighted average of 108.0 million basic shares outstanding in 2026 Q2.
What is Oric Pharmaceuticals' market cap?
Based on its latest closing price, Oric Pharmaceuticals (ORIC) has a market capitalization of about $1.22B.
When does Oric Pharmaceuticals' fiscal year end?
Oric Pharmaceuticals' fiscal year end, as registered with the SEC, is December 31.
Where is Oric Pharmaceuticals headquartered?
Oric Pharmaceuticals lists its business address in South San Francisco, California in its SEC filings.